

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 12 of 16 of Communication in Response to January 18, 2011 Final
Office Action and Supplemental Information Disclosure Statement

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the items listed below which are also listed on the Substitute PTO-1449 form attached hereto as **Exhibit A**. Items 1-4 are U.S. Patents and U.S. Patent Application Publications. Copies of these documents are not attached hereto as permitted by 37 C.F.R. §1.98(a)(2)(ii). Copies of items 5-28 are enclosed herewith as **Exhibits 1-24**, respectively.

1. U.S. Patent No. 7,662,392 issued to Silviu Itescu on February 16, 2010;
2. U.S. Patent No. 7,887,796 issued to Silviu Itescu on February 15, 2011;
3. U.S. Patent Application Publication No. 2008-0057069 published March 6, 2008, Itescu;
4. U.S. Patent Application Publication No. 2009-0142296 published June 4, 2009, Itescu;
5. European Publication No. EP2292631, published March 9, 2011; (**Exhibit 1**)
6. Boyle et al. (1998) "Inhibition of Interleukin-8 Blocks Myocardial Ischemia-Reperfusion Injury", J Thoracic and Cardiovascular Surgery 116: 114-121; (**Exhibit 2**)
7. Damas et al. (2000) "CXC-Chemokines, A New Group Of Cytokines In Congestive Heart Failure - Possible Role of Platelets and Monocytes", Cardiovascular Research 45:428-436; (**Exhibit 3**)
8. Higuchi et al. (2009) "Direct Injection of Kit Ligand-2 Lentivirus Improves Cardiac Repair and Rescues Mice

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 13 of 16 of Communication in Response to January 18, 2011 Final
Office Action and Supplemental Information Disclosure Statement

Post-myocardial Infraction", Mol. Ther. 17:262-268;
(Exhibit 4)

9. Himmelmann et al. (1999) "New Information on the Role of Beta-blockers in Cardiac Therapy", Cardiovasc Drugs Therapy, 13:469-477; **(Exhibit 5)**
10. Jayasankar et al. (2004) "Targeted Overexpression of Growth Hormone by Adenoviral Gene Transfer Preserves Myocardial Function and Ventricular Geometry in Ischemiccardiomyopathy", J Mol Cell Cardiol. 36:531-538; **(Exhibit 6)**
11. Schuster et al. (2002) "Stromal Derived Growth Factor (SDF)-1 Augments Myocardial Neovascularization and Cardiomyocyte Regeneration Induced By Human Bone Marrow Angioblasts", Circulation 106:65; **(Exhibit 7)**
12. Tendera et al. (2005) "Clinical Trials Using Autologous Bone Marrow and Peripheral Blood-derived Progenitor Cells in Patients With Acute Myocardial Infarction", Folia Histochemica Cytobiol, 43(4):233-235; **(Exhibit 8)**
13. Walter et al. (2002) "Endothelial Progenitor Cell: Regulation and Contribution to Adult Neovascularization", Herz, 27:579-588; **(Exhibit 9)**
14. Zampetaki et al. (2008), "Vascular Repair by Endothelial Progenitor Cells", Cardiovasc Res 78:413-421; **(Exhibit 10)**
15. October 7, 2010 Official Action issued in connection with Canadian Patent Application No. 2,412,436; **(Exhibit 11)**

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 14 of 16 of Communication in Response to January 18, 2011 Final
Office Action and Supplemental Information Disclosure Statement

16. March 18, 2011 Office Action issued in connection with
U.S. Serial No. 11/894,581; **(Exhibit 12)**
17. December 7, 2010 Office Action issued in connection
with U.S. Serial No. 11/894,555; **(Exhibit 13)**
18. February 16, 2011 Office Action issued in connection
with U.S. Serial No. 12/657,264; **(Exhibit 14)**
19. June 8, 2011 Office Action issued in connection with
U.S. Serial No. 12/657,264; **(Exhibit 15)**
20. February 23, 2011 Official Action issued in connection
with European Patent Application No. EP01942041.3;
(Exhibit 16)
21. April 26, 2011 European Search Report and Opinion
issued in connection with European Patent Application
No. EP10012751.1; **(Exhibit 17)**
22. October 12, 2010 Notice of Allowance issued in
connection with U.S. Serial No. 10/512,518; **(Exhibit
18)**
23. November 17, 2010 Official Action issued in connection
with Canadian Patent Application No. 2,482,996;
(Exhibit 19)
24. February 7, 2011 Communication issued in connection
with European Patent Application No. EP10164397.1;
(Exhibit 20)
25. Extended European Search Report issued in connection
with European Patent Application No. EP10164397.1;
(Exhibit 21)
26. March 14, 2011 Communication Pursuant to Rules 70(2)

Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 15 of 16 of Communication in Response to January 18, 2011 Final
Office Action and Supplemental Information Disclosure Statement

and 70a(2) EPC and Reference to Rule 39(1) EPC issued
in connection with European Patent Application No.
EP10164397.1; **(Exhibit 22)**

27. January 26, 2011 Office Action issued in connection
with Israeli Patent Application No. 164671; **(Exhibit
23)** and
28. April 5, 2011 Decision of Dismissal of Amendment and
Decision of Rejection issued in connection with
Japanese Patent Application No. 2003-587162 **(Exhibit
24)**.

The Examiner is respectfully requested to make of record the
items listed on the PTO Form 1449 Substitute by initialing and
dating the attached PTO Form 1449 Substitute, and returning a
copy of the initialed and dated form to applicant's undersigned
attorney.



This Supplemental Information Disclosure Statement is being
submitted under 37 C.F.R. §§1.97(b)(4). Accordingly, no fee is
necessary for filing this Supplemental Information Disclosure
Statement.


Applicant : Silviu Itescu
U.S. Serial No. : 10/693,480
Filed : October 23, 2003
Page 16 of 16 of Communication in Response to January 18, 2011 Final
Office Action and Supplemental Information Disclosure Statement

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the total fee of \$960.00, including a \$555.00 fee for a three-month extension of time and a \$405.00 fee for filing an RCE, for which the authorization to charge Deposit Account No. 03-3125 has been given above, is deemed necessary in connection with the filing of this Communication and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Certificate of Transmission	
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on July 18, 2011.	
 John P. White Reg. No. 28,678	 Date


John R. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
30 Rockefeller Plaza
20th Floor
New York, New York 10112
(212) 278-0400